The Cost-effectiveness of Treating Diabetic Lower Extremity Ulcers with Becaplermin (Regranex): A Core Model with an Application Using Swedish Cost Data
- 1 November 2000
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 3, S39-S46
- https://doi.org/10.1046/j.1524-4733.2000.36027.x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Efficacy and safety of becaplermin (recombinant human platelet‐derived growth factor‐BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studiesWound Repair and Regeneration, 1999
- The burden of diabetic foot ulcersThe American Journal of Surgery, 1998
- Cost-Effective Management of Diabetic Foot UlcersPharmacoEconomics, 1997
- Long-Term Costs for Foot Ulcers in Diabetic Patients in a Multidisciplinary SettingFoot & Ankle International, 1995
- Topical Treatment of Diabetic Foot Ulcers: an Economic Analysis of Treatment Alternatives and StrategiesDiabetic Medicine, 1995
- Diabetic foot ulcers in a multidisciplinary setting An economic analysis of primary healing and healing with amputationJournal of Internal Medicine, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993
- The Economic Costs of Non—Insulin-Dependent Diabetes MellitusJAMA, 1989
- The Dysvascular Foot: A System for Diagnosis and TreatmentFoot & Ankle, 1981